{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:28:48Z","timestamp":1793856528175,"version":"4.6.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01DK054254"],"award-info":[{"award-number":["R01DK054254"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01DK121797"],"award-info":[{"award-number":["R01DK121797"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01DK124126"],"award-info":[{"award-number":["R01DK124126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01DK129877"],"award-info":[{"award-number":["R01DK129877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.metabol.2023.155607","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T11:29:53Z","timestamp":1685705393000},"page":"155607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Hepatic insulin receptor: new views on the mechanisms of liver disease"],"prefix":"10.1016","volume":"145","author":[{"given":"Wang-Hsin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ronald","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Terry D.","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0005","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2337\/db19-0098","article-title":"Hypothesis: role of reduced hepatic insulin clearance in the pathogenesis of type 2 diabetes","volume":"68","author":"Bergman","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.amepre.2011.10.026","article-title":"Obesity and severe obesity forecasts through 2030","volume":"42","author":"Finkelstein","year":"2012","journal-title":"Am J Prev Med"},{"issue":"25","key":"10.1016\/j.metabol.2023.155607_bb0020","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155607_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32467","article-title":"Hepatic kinome atlas: an in-depth identification of kinase pathways in liver fibrosis of humans and rodents","author":"Creeden","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0030","doi-asserted-by":"crossref","first-page":"G668","DOI":"10.1152\/ajpgi.00026.2018","article-title":"Biliverdin reductase and bilirubin in hepatic disease","volume":"314","author":"Weaver","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0045","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0055","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0060","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.47892\/rgp.2022.422.1376","article-title":"Normal transaminases in obese patients with metabolic associated steatohepatitis (MASH): a cohort of Peruvian patients","volume":"42","author":"Lozano","year":"2022","journal-title":"Rev Gastroenterol Peru"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10010197","article-title":"Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease","volume":"10","author":"Moreno-Vedia","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.metabol.2023.155607_bb0075","doi-asserted-by":"crossref","first-page":"e3230","DOI":"10.1210\/clinem\/dgac292","article-title":"Serum thrombospondin-2 levels are closely associated with the severity of metabolic syndrome and metabolic associated fatty liver disease","volume":"107","author":"Wu","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.gastrohep.2022.02.005","article-title":"Metabolic-associated fatty liver disease: from simple steatosis toward liver cirrhosis and potential complications. Proceedings of the third translational hepatology meeting, organized by the Spanish Association for the Study of the Liver (AEEH)","volume":"45","author":"Gallego-Dur\u00e1n","year":"2022","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.metabol.2023.155607_bb0090","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0095","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.metabol.2023.155607_bb0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"39","key":"10.1016\/j.metabol.2023.155607_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060237","article-title":"It's not how fat you are, it's what you do with it that counts","volume":"6","author":"Virtue","year":"2008","journal-title":"PLoS Biol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0125","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/diabetes.54.6.1649","article-title":"Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans","volume":"54","author":"Meier","year":"2005","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.metabol.2023.155607_bb0130","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.2337\/db17-0413","article-title":"Hepatic but not extrahepatic insulin clearance is lower in African American than in European American women","volume":"66","author":"Piccinini","year":"2017","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0135","first-page":"198","article-title":"Hepatic insulin clearance: mechanism and physiology","volume":"34","author":"Najjar","year":"2019","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.metabol.2023.155607_bb0140","article-title":"Insulin clearance in health and disease","author":"Najjar","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"8","key":"10.1016\/j.metabol.2023.155607_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081899","article-title":"Regulation of insulin clearance by non-esterified fatty acids","volume":"10","author":"Najjar","year":"2022","journal-title":"Biomedicines"},{"issue":"13\u201314","key":"10.1016\/j.metabol.2023.155607_bb0150","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.clinbiochem.2009.05.018","article-title":"Hepatic insulin resistance, metabolic syndrome and cardiovascular disease","volume":"42","author":"Meshkani","year":"2009","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","article-title":"Resolving the paradox of hepatic insulin resistance","volume":"7","author":"Santoleri","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1083\/jcb.72.2.441","article-title":"Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study","volume":"72","author":"Blouin","year":"1977","journal-title":"J Cell Biol"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0165","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1083\/jcb.201903090","article-title":"The cell biology of the hepatocyte: a membrane trafficking machine","volume":"218","author":"Schulze","year":"2019","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1097-2765(05)00015-8","article-title":"Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction","volume":"6","author":"Michael","year":"2000","journal-title":"Mol Cell"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","article-title":"Unraveling the regulation of hepatic metabolism by insulin","volume":"28","author":"Titchenell","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2023.155607_bb0180","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0185","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cell.2017.09.045","article-title":"Selective inhibition of FOXO1 activator\/repressor balance modulates hepatic glucose handling","volume":"171","author":"Langlet","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2023.155607_bb0190","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1038\/ncomms8400","article-title":"PI3K-C2gamma is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling","volume":"6","author":"Braccini","year":"2015","journal-title":"Nat Commun"},{"issue":"Pt 5","key":"10.1016\/j.metabol.2023.155607_bb0195","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1242\/jcs.093773","article-title":"Classes of phosphoinositide 3-kinases at a glance","volume":"127","author":"Jean","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1016\/j.metabol.2023.155607_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2021.08.003","article-title":"FKBP51 and the molecular chaperoning of metabolism","author":"Smedlund","year":"2021","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0205","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tem.2015.02.001","article-title":"Biliverdin reductase isozymes in metabolism","volume":"26","author":"O\u2019Brien","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155607_bb0210","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M116.731703","article-title":"Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) alpha","author":"Hinds","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155607_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective","volume":"48","author":"Han","year":"2016","journal-title":"Exp Mol Med"},{"issue":"13","key":"10.1016\/j.metabol.2023.155607_bb0220","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1016\/j.celrep.2019.08.066","article-title":"The protein phosphatase 1 complex is a direct target of AKT that links insulin signaling to hepatic glycogen deposition","volume":"28","author":"Li","year":"2019","journal-title":"Cell Rep"},{"issue":"14","key":"10.1016\/j.metabol.2023.155607_bb0225","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1073\/pnas.1921694117","article-title":"Metabolic control analysis of hepatic glycogen synthesis in vivo","volume":"117","author":"Nozaki","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"40","key":"10.1016\/j.metabol.2023.155607_bb0230","doi-asserted-by":"crossref","first-page":"16184","DOI":"10.1073\/pnas.1213343109","article-title":"Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase","volume":"109","author":"Owen","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.metabol.2023.155607_bb0235","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0240","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1172\/JCI137050","article-title":"Insulin-stimulated lipogenesis gets an epigenetic makeover","volume":"130","author":"Manuel","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2023.155607_bb0245","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00153.2019","article-title":"The loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet-induced obesity","author":"Stec","year":"2019","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153427","article-title":"Bilirubin binding to PPARalpha inhibits lipid accumulation","volume":"11","author":"Stec","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2023.155607_bb0255","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.013700","article-title":"Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor alpha","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155607_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbadis.2014.12.011","article-title":"Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARalpha","volume":"1852","author":"Komatsu","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2023.155607_bb0275","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M116.752311","article-title":"Glucocorticoid receptor beta induces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (PPAR) alpha","author":"Marino","year":"2016","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.metabol.2023.155607_bb0280","doi-asserted-by":"crossref","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","article-title":"Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet-induced obesity","volume":"317","author":"Stec","year":"2019","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010004","article-title":"Adipose-specific PPARalpha knockout mice have increased lipogenesis by PASK-SREBP1 signaling and a polarity shift to inflammatory macrophages in white adipose tissue","volume":"11","author":"Hinds","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2023.155607_bb0290","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00057.2023","article-title":"The loss of hepatic PPARalpha in mice causes hypertension and cardiovascular disease","author":"Badmus","year":"2023","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0295","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1038\/s41598-020-63579-3","article-title":"Hepatocyte-specific deletion of Pparalpha promotes NAFLD in the context of obesity","volume":"10","author":"Regnier","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2023.155607_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594574","article-title":"Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma beta-hydroxybutyrate","volume":"11","author":"Hinds","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0305","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M700033-JLR200","article-title":"SREBP-1-independent regulation of lipogenic gene expression in adipocytes","volume":"48","author":"Sekiya","year":"2007","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0310","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"10","key":"10.1016\/j.metabol.2023.155607_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/nu10101383","article-title":"Regulation and metabolic significance of de novo lipogenesis in adipose tissues","volume":"10","author":"Song","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0320","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/diab.39.4.501","article-title":"Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity","volume":"39","author":"Ward","year":"1990","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cmet.2005.06.001","article-title":"Insulin acutely decreases hepatic fatty acid synthase activity","volume":"2","author":"Najjar","year":"2005","journal-title":"Cell Metab"},{"issue":"15","key":"10.1016\/j.metabol.2023.155607_bb0330","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.1074\/jbc.M116.714014","article-title":"PPAR\u03b1 (peroxisome proliferator-activated receptor \u03b1) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition","volume":"291","author":"Ramakrishnan","year":"2016","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0335","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease","volume":"44","author":"Ter Horst","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/metabo13020215","article-title":"Bilirubin nanoparticle treatment in obese mice inhibits hepatic ceramide production and remodels liver fat content","volume":"13","author":"Kipp","year":"2023","journal-title":"Metabolites"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0345","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/biom13020252","article-title":"Suppressing hepatic UGT1A1 increases plasma bilirubin, lowers plasma Urobilin, reorganizes kinase signaling pathways and lipid species and improves fatty liver disease","volume":"13","author":"Bates","year":"2023","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.metabol.2023.155607_bb0350","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2012.04.005","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2007.01.002","article-title":"Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance","volume":"5","author":"Holland","year":"2007","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.metabol.2023.155607_bb0360","first-page":"608","article-title":"Insulin degradation: progress and potential*","volume":"19","author":"Duckworth","year":"1998","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0365","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1083\/jcb.201802095","article-title":"The cell biology of systemic insulin function","volume":"217","author":"Tokarz","year":"2018","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1043-2760(02)00608-2","article-title":"Regulation of insulin action by CEACAM1","volume":"13","author":"Najjar","year":"2002","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0375","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ng840","article-title":"CEACAM1 regulates insulin clearance in liver","volume":"30","author":"Poy","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2023.155607_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154735","article-title":"Loss of postprandial insulin clearance control by insulin-degrading enzyme drives dysmetabolism traits","volume":"118","author":"Borges","year":"2021","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0385","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","article-title":"The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia","volume":"33","author":"Sylow","year":"2021","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0390","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/db13-0696","article-title":"A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young south Asian men but not in Caucasian men","volume":"63","author":"Bakker","year":"2014","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0395","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00125-017-4511-0","article-title":"Adapting to insulin resistance in obesity: role of insulin secretion and clearance","volume":"61","author":"Jung","year":"2018","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0400","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2337\/dc21-0545","article-title":"New insights on the interactions between insulin clearance and the main glucose homeostasis mechanisms","volume":"44","author":"Bizzotto","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0405","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2337\/db19-1152","article-title":"Adaptation of insulin clearance to metabolic demand is a key determinant of glucose tolerance","volume":"70","author":"Gastaldelli","year":"2021","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0410","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jdi.12717","article-title":"Impaired insulin clearance as a cause rather than a consequence of insulin resistance","volume":"8","author":"Watada","year":"2017","journal-title":"J Diabetes Investig"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0415","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3904\/kjim.2005.20.2.146","article-title":"Increased expression of glucocorticoid receptor beta messenger RNA in patients with ankylosing spondylitis","volume":"20","author":"Lee","year":"2005","journal-title":"Korean J Intern Med"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0420","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00125-020-05348-5","article-title":"Lower insulin clearance is associated with increased risk of type 2 diabetes in native Americans","volume":"64","author":"Shah","year":"2021","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0425","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1152\/ajpendo.00478.2015","article-title":"The glucocorticoid receptor: cause of or cure for obesity?","volume":"310","author":"John","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0430","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1089\/met.2017.0001","article-title":"The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease","volume":"15","author":"Ko","year":"2017","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0435","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0440","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142245","article-title":"Severe insulin resistance syndromes","volume":"131","author":"Angelidi","year":"2021","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.metabol.2023.155607_bb0445","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.2337\/db14-0109","article-title":"Genetic insulin resistance is a potent regulator of gene expression and proliferation in human iPS cells","volume":"63","author":"Iovino","year":"2014","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.metabol.2023.155607_bb0450","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11886-016-0755-4","article-title":"Genetics of insulin resistance and the metabolic syndrome","volume":"18","author":"Brown","year":"2016","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0455","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/er.2010-0020","article-title":"Genetic syndromes of severe insulin resistance","volume":"32","author":"Semple","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2023.155607_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108072","article-title":"CRISPR Cas9-mediated deletion of biliverdin reductase A (BVRA) in mouse liver cells induces oxidative stress and lipid accumulation","volume":"672","author":"Gordon","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.metabol.2023.155607_bb0465","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mehy.2016.08.013","article-title":"Does bilirubin prevent hepatic steatosis through activation of the PPARalpha nuclear receptor?","volume":"95","author":"Hinds","year":"2016","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0470","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2023.155607_bb0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2019.01.008","article-title":"Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis","volume":"93","author":"Ghadieh","year":"2019","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0480","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0485","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/dom.14076","article-title":"Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: a cross-sectional and longitudinal study from the Yale Pediatric NAFLD cohort","volume":"22","author":"Trico","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2023.155607_bb0490","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1746-1596-6-40","article-title":"The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes","volume":"6","author":"Lee","year":"2011","journal-title":"Diagn Pathol"},{"issue":"17","key":"10.1016\/j.metabol.2023.155607_bb0495","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0500","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Cell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0505","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0510","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/jcm3020453","article-title":"The roles of vitamin a in the regulation of carbohydrate, lipid, and protein metabolism","volume":"3","author":"Chen","year":"2014","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13578-020-00509-w","article-title":"Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis","volume":"11","author":"Hwang","year":"2021","journal-title":"Cell Biosci"},{"issue":"10","key":"10.1016\/j.metabol.2023.155607_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101153","article-title":"TGR5 activation modulates an inhibitory effect on liver fibrosis development mediated by anagliptin in diabetic rats","volume":"8","author":"Kaya","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0525","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-017-4470-9","article-title":"Activation of insulin-PI3K\/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis","volume":"62","author":"Cai","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0530","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.mce.2013.09.020","article-title":"Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K\/AKT and ERK pathways","volume":"382","author":"Zhang","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0535","first-page":"69","article-title":"Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis","volume":"2010","author":"Ghosh","year":"2010","journal-title":"Hepat Med"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0540","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1053\/j.gastro.2008.08.007","article-title":"Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice","volume":"135","author":"Lee","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2023.155607_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154801","article-title":"Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1","volume":"121","author":"Helal","year":"2021","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2023.155607_bb0550","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3390\/ijms19103110","article-title":"CEACAM1 in liver injury, metabolic and immune regulation","volume":"19","author":"Horst","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155607_bb0555","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fendo.2017.00008","article-title":"Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease","volume":"8","author":"Heinrich","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.metabol.2023.155607_bb0560","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.metabol.2023.155607_bb0565","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2023.155607_bb0570","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: a critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.metabol.2023.155607_bb0575","doi-asserted-by":"crossref","DOI":"10.1210\/en.2015-1996","article-title":"FKBP51 null mice are resistant to diet-induced obesity and the PPARgamma agonist rosiglitazone","author":"Stechschulte","year":"2016","journal-title":"Endocrinology"},{"issue":"50","key":"10.1016\/j.metabol.2023.155607_bb0580","doi-asserted-by":"crossref","first-page":"42911","DOI":"10.1074\/jbc.M111.311662","article-title":"Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma (PPARgamma)","volume":"286","author":"Hinds","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2023.155607_bb0585","doi-asserted-by":"crossref","first-page":"4810672","DOI":"10.1155\/2017\/4810672","article-title":"Deciphering the roles of thiazolidinediones and PPARgamma in bladder Cancer","volume":"2017","author":"Chiu","year":"2017","journal-title":"PPAR Res"},{"issue":"11","key":"10.1016\/j.metabol.2023.155607_bb0590","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.metabol.2023.155607_bb0595","doi-asserted-by":"crossref","first-page":"15712","DOI":"10.1073\/pnas.2536828100","article-title":"Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle","volume":"100","author":"He","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0600","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13643-019-1200-8","article-title":"Diabetes drugs for nonalcoholic fatty liver disease: a systematic review","volume":"8","author":"Blazina","year":"2019","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.metabol.2023.155607_bb0605","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/gut.2005.085399","article-title":"Thiazolidinediones and hepatic fibrosis: don\u2019t wait too long","volume":"55","author":"Marra","year":"2006","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0610","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","article-title":"Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells","volume":"119","author":"Marra","year":"2000","journal-title":"Gastroenterology"},{"issue":"46","key":"10.1016\/j.metabol.2023.155607_bb0615","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.metabol.2023.155607_bb0620","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/pds.1804","article-title":"Case series of liver failure associated with rosiglitazone and pioglitazone","volume":"18","author":"Floyd","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.metabol.2023.155607_bb0625","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Antidiabetic Agents","year":"2012"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0630","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0635","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4254\/wjh.v6.i4.199","article-title":"Insulin sensitizers for the treatment of non-alcoholic fatty liver disease","volume":"6","author":"Ozturk","year":"2014","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0640","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/br.2021.1425","article-title":"Effects of obesity and 10 weeks metformin treatment on liver steatosis","volume":"14","author":"Hakkak","year":"2021","journal-title":"Biomed Rep"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0645","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.32235","article-title":"A GLP-1\/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome","volume":"75","author":"Kim","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0650","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.clinre.2013.10.013","article-title":"Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients","volume":"38","author":"Blaslov","year":"2014","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9","key":"10.1016\/j.metabol.2023.155607_bb0655","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0660","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0665","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.metabol.2023.155607_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.935180","article-title":"Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0675","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep4.1117","article-title":"Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis","volume":"2","author":"Ghadieh","year":"2018","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0690","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/liv.14799","article-title":"Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: a real-world data analysis","volume":"41","author":"Colosimo","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0695","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/j.1550-8528.1997.tb00650.x","article-title":"Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome?","volume":"5","author":"Torgerson","year":"1997","journal-title":"Obes Res"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0700","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1210\/en.2013-1667","article-title":"Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation","volume":"155","author":"Dong","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0705","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/antiox12010170","article-title":"Bilirubin levels are negatively correlated with adiposity in obese men and women, and its catabolized product, urobilin, is positively associated with insulin resistance","volume":"12","author":"Kipp","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.metabol.2023.155607_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594574","article-title":"Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma \u03b2-hydroxybutyrate","volume":"11","author":"Hinds","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.metabol.2023.155607_bb0715","doi-asserted-by":"crossref","first-page":"E191","DOI":"10.1152\/ajpendo.00405.2020","article-title":"Bilirubin as a metabolic hormone: the physiological relevance of low levels","volume":"320","author":"Creeden","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2023.155607_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2018.01.002","article-title":"Bilirubin in the liver-gut signaling axis","author":"Hamoud","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0725","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1152\/ajpendo.00396.2016","article-title":"Mice with hyperbilirubinemia due to Gilbert\u2019s Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha","volume":"312","author":"Hinds","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.metabol.2023.155607_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249493","article-title":"Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease","volume":"21","author":"Stec","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2023.155607_bb0735","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13931","article-title":"Powering the powerhouse: Heme oxygenase-1 regulates mitochondrial function in non-alcoholic fatty liver disease (NAFLD)","author":"Hinds","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"issue":"10","key":"10.1016\/j.metabol.2023.155607_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102975","article-title":"Identification of binding regions of bilirubin in the ligand-binding pocket of the peroxisome proliferator-activated receptor-A (PPARalpha)","volume":"26","author":"Gordon","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.metabol.2023.155607_bb0745","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1152\/physiolgenomics.00028.2019","article-title":"RNA sequencing in human HepG2 hepatocytes reveals PPAR-alpha mediates transcriptome responsiveness of bilirubin","volume":"51","author":"Gordon","year":"2019","journal-title":"Physiol Genomics"},{"issue":"29","key":"10.1016\/j.metabol.2023.155607_bb0750","doi-asserted-by":"crossref","first-page":"9804","DOI":"10.1074\/jbc.RA120.013700","article-title":"Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor \u03b1","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.metabol.2023.155607_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030387","article-title":"Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice","volume":"10","author":"Stec","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.metabol.2023.155607_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102152","article-title":"Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance","volume":"47","author":"Chen","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2023.155607_bb0765","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease","author":"Badmus","year":"2023","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"10.1016\/j.metabol.2023.155607_bb0770","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11906-019-0994-z","article-title":"Bilirubin safeguards cardiorenal and metabolic diseases: a protective role in health","volume":"21","author":"Hinds","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"4","key":"10.1016\/j.metabol.2023.155607_bb0775","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/HYPERTENSIONAHA.118.11130","article-title":"Bilirubin, a cardiometabolic signaling molecule","volume":"72","author":"Hinds","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2023.155607_bb0780","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.metabol.2023.155607_bb0785","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12876-021-01773-x","article-title":"Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Gastroenterol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049523002111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:31:30Z","timestamp":1758429090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049523002111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":157,"alternative-id":["S0026049523002111"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155607","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic insulin receptor: new views on the mechanisms of liver disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2023.155607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155607"}}